Abstract:
A door-unlatching device including a lower actuator including a foot-pad, an upper actuator including a lever-arm and a handle-mount attachable to a handle of door-latch, and a link coupled to the foot-pad and the lever-arm, wherein the lever-arm is movable between a first position and a second position relative to the handle-mount. It can be set to either engaged mode which allows either hand or foot to operate; or disengaged mode to allow only hand to operate which the door can also be locked from entry as by a normal door latch.
Abstract:
The present disclosure relates to mitigating read disturb in a cross-point memory. An apparatus may include a memory controller configured to select a target memory cell for a memory access operation. The memory controller includes a sense module configured to determine whether a snap back event occurs during a sensing interval; and a write back module configured to write back a logic one to the memory cell if a snap back event is detected.
Abstract:
Technology for writing data to a phase change memory array is disclosed. In an example, a method may include identifying mask logic for masking cells in the phase change memory array and routing the mask logic to the cells. The method may further include routing input data to the cells. Set and reset pulses for the cells may be selectively prevented or inhibited based on the mask logic.
Abstract:
Rapid and uniform temperature changes in the wells of a microplate or any thin-walled plate that contains an array of reaction wells, or in the channels of a multi-channel microfluidics device, are achieved by the use of a thermal block with thermoelectric heating/cooling elements built into the block, or by the use of a thermal block with wedges protruding from its lower surface, with thermoelectric elements placed in surface contact with the angled sides of each wedge.
Abstract:
Provided herein are inhibitors of CYP17 enzyme. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat androgen-dependent diseases, disorders and conditions.
Abstract:
A system, apparatus and method for using modular microscopes is disclosed. Connecting the housings of the individual microscope modules provide the structural framework of the modular microscope. Furthermore, the modular microscope can include specialized software, the distribution and use of which can be controlled using security keys or identifiers stored on one or more of the microscope modules. The security keys and identifiers can be based on calibration data associated with the physical, electrical, or optical properties of one of more of the modules. The illumination modules disclosed provide for selectable wavelengths and controllable levels of output illumination for both bright field and dark field illumination.
Abstract:
Horizontal electrophoresis is performed in a cell that includes a tank and a pair of electrodes, each mounted on an electrode support that is easily inserted into and removed from the tank, and once inserted, is secured in position by one or more spring-loaded, manual-release locking features.
Abstract:
Provided herein are inhibitors of CYP17 enzyme. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat androgen-dependent diseases, disorders and conditions.
Abstract:
A compound having the structure set forth in Formula (I) and Formula (II) wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.
Abstract:
A compound having the structure set forth in Formula (I) or Formula (II): Formula (I) Formula (II) wherein the variables Y, R 1 , R 2 , R 3 , and R 4 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.